Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 17;103(16):1222-6.
doi: 10.1093/jnci/djr246. Epub 2011 Jul 15.

Opportunities and challenges in the development of experimental drug combinations for cancer

Rachel W Humphrey  1 , Laura M Brockway-Lunardi, David T Bonk, Kathleen M Dohoney, James H Doroshow, Sandra J Meech, Mark J Ratain, Suzanne L Topalian, Drew M Pardoll
Affiliations

Opportunities and challenges in the development of experimental drug combinations for cancer

Rachel W Humphrey et al. J Natl Cancer Inst. .

Abstract

It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

PubMed Disclaimer

References

    1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med. 2010;363(9):809–819. - PMC - PubMed
    1. Flaherty KT. BRAF inhibition in melanoma provides new insights into oncogene targeted therapy development. American Association of Cancer Research Annual Meeting, April 6, 2011, Orlando, FL.
    1. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–695. - PMC - PubMed
    1. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–972. - PMC - PubMed
    1. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977. - PMC - PubMed

Publication types

MeSH terms

Substances